Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Common Equity (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Common Equity for 4 consecutive years, with $526.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 31.21% to $526.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $526.9 million through Dec 2025, up 31.21% year-over-year, with the annual reading at $526.9 million for FY2025, 31.21% up from the prior year.
  • Common Equity for Q4 2025 was $526.9 million at Centessa Pharmaceuticals, up from $301.6 million in the prior quarter.
  • The five-year high for Common Equity was $526.9 million in Q4 2025, with the low at $215.2 million in Q1 2024.
  • Average Common Equity over 4 years is $352.3 million, with a median of $340.5 million recorded in 2022.
  • The sharpest move saw Common Equity soared 92.43% in 2024, then crashed 39.58% in 2025.
  • Over 4 years, Common Equity stood at $336.2 million in 2022, then fell by 29.72% to $236.2 million in 2023, then soared by 69.97% to $401.5 million in 2024, then surged by 31.21% to $526.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $526.9 million, $301.6 million, and $344.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.